<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-32870" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bumetanide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sidhu</surname>
            <given-names>Gursharan</given-names>
          </name>
          <aff>Avalon University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Puckett</surname>
            <given-names>Yana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gursharan Sidhu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yana Puckett declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-32870.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bumetanide is FDA-approved for managing various edematous conditions secondary to cardiac failure or hepatic or renal disease, including nephrotic syndrome. It is a member of the loop diuretic class of drugs. This activity reviews bumetanide's indications, action, and contraindications as a valuable agent in treating and managing various edematous conditions secondary to cardiac failure or hepatic or renal disease. This activity will highlight the mechanism of action, adverse effects, and other key factors such as dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in the treatment and care of patients with edematous conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of bumetanide.</p></list-item><list-item><p>Describe the potential adverse effects of bumetanide.</p></list-item><list-item><p>Review the appropriate monitoring of patients receiving bumetanide.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance bumetanide and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32870&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32870">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-32870.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bumetanide has United States Food and Drug Administration (FDA) approval for managing various edematous conditions secondary to cardiac failure with or without ascites or hepatic/renal disease, including nephrotic syndrome.<xref ref-type="bibr" rid="article-32870.r1">[1]</xref> It may also&#x000a0;be indicated for refractory edema resistant to other loop diuretics.</p>
        <p>Bumetanide&#x000a0;may be used alone or in conjunction with other antihypertensive agents in treating hypertension, although this is not an FDA-approved indication.&#x000a0;Treating acute hypercalcemia is also an off-label indication for the drug.<xref ref-type="bibr" rid="article-32870.r2">[2]</xref>&#x000a0;Bumetanide may be an appropriate option&#x000a0;for patients who have an allergic reaction to furosemide, another loop diuretic.</p>
        <p>Recent studies show seizures and&#x000a0;behavioral&#x000a0;problems in&#x000a0;patients&#x000a0;with&#x000a0;tuberous sclerosis may be treated by agents that enhance&#x000a0;GABA-anergic&#x000a0;transmission by influencing chloride regulation.<xref ref-type="bibr" rid="article-32870.r3">[3]</xref>&#x000a0;Using&#x000a0;bumetanide&#x000a0;for this purpose is also not FDA-approved.&#x000a0;</p>
      </sec>
      <sec id="article-32870.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Diuretics play a crucial role in treating edema and hypertension by causing the induction of a&#x000a0;negative balance of solute and water. Loop diuretics are physiologically the most potent family of diuretics, as demonstrated by possessing&#x000a0;natriuretic and chloriuretic potency of the diuretic&#x000a0;drug class. These agents&#x000a0;potentially increase Na and Cl excretion to&#x000a0;over 25% of the filtered load. Although they have no direct epithelial effect on segments such as the thin descending limb of Henle and the thick ascending limb of Henle, many diuretics decrease fluid reabsorption by abolishing the papillary osmotic gradient. Most of the loop diuretics have a&#x000a0;direct inhibitory effect on the cotransport process, specifically by interfering with the active chloride transport secondary to the presence of&#x000a0;sodium. This is located on the luminal membrane of the segment. Loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid) inhibit the concentrating mechanisms in the medullary segment, whereas diuretics such as thiazides are effective primarily in the cortical segment and inhibit the urinary diluting mechanism.<xref ref-type="bibr" rid="article-32870.r4">[4]</xref><xref ref-type="bibr" rid="article-32870.r5">[5]</xref></p>
        <p>Bumetanide&#x000a0;inhibits the reabsorption of sodium and chloride in the ascending loop of Henle and proximal renal tubule, which interferes with the chloride-binding&#x000a0;cotransport&#x000a0;system. This mechanism increases the excretion of water, magnesium phosphate, sodium chloride, and calcium. It decreases both free water clearance and solute-free water reabsorption and increases sodium chloride excretion to the distal tubule (natriuresis), calciuria, phosphaturia, and minimal bicarbonaturia. Studies have shown the&#x000a0;onset&#x000a0;of diuretic action&#x000a0;occurs during 0&#x000a0;to 30&#x000a0;minutes following intravenous use and 30&#x000a0;to 60&#x000a0;min&#x000a0;following oral administration. The diuretic effect and the total duration of action last for 3&#x000a0;to 4&#x000a0;hours (270 min) with similar net urine output between intravenous and oral administration.<xref ref-type="bibr" rid="article-32870.r6">[6]</xref>&#x000a0;The peak of the drug's action occurs&#x000a0;at 90 minutes after oral&#x000a0;administration.<xref ref-type="bibr" rid="article-32870.r1">[1]</xref></p>
      </sec>
      <sec id="article-32870.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Bumetanide is available in oral and injectable administrations (intravenous, intramuscular).&#x000a0;Bumetanide&#x000a0;is rapidly absorbed after oral and intravenous formulations. 95% of the drug&#x000a0;extensively binds to plasma proteins and&#x000a0;is eliminated&#x000a0;by the metabolism of the butyl side chain and partially removed through urine excretion. The&#x000a0;apparent&#x000a0;half-life is 1.0 to 1.5 hours, and the volume of distribution is about 25 liters.&#x000a0;Plasma clearance is 225 to 228 ml/min.</p>
        <p>Bumetanide has high bioavailability, between 80% to 100%; this means that oral and IV bioavailability are roughly equivalent, constructed to furosemide, where oral doses should be roughly double IV doses.<xref ref-type="bibr" rid="article-32870.r7">[7]</xref></p>
        <p>The different modes of administration of&#x000a0;bumetanide&#x000a0;with dosages are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bumetanide oral tablet: 0.5 mg, 1 mg, 2 mg</p>
          </list-item>
          <list-item>
            <p>Bumetanide&#x000a0;intramuscular/intravenous injection&#x000a0;solution: 0.25 mg/1 mL</p>
          </list-item>
        </list>
        <p>Dosing regimens based on the condition are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Edema
<list list-type="bullet"><list-item><p>Oral route of administration:
<list list-type="bullet"><list-item><p>0.5 to 10 mg per day orally divided once or twice daily. Initiate treatment of 0.5 to 2.0 mg per day, repeating every 4 to 5 hours until obtaining the appropriate response. The maximum dosage is 10 mg per day.</p></list-item></list>
</p></list-item><list-item><p>Intramuscular/intravenous route of administration:
<list list-type="bullet"><list-item><p>0.5 to 10 mg per day&#x000a0;IM/IV divided once or twice daily. Initiate treatment 0.5 to&#x000a0;1.0 mg per day over 1 to 2 minutes, repeating every&#x000a0;2 to 3 hours until obtaining the appropriate response. The maximum dosage is 10 mg per day.
<list list-type="bullet"><list-item><p>An alternate day schedule or schedule of three to four days on with a one to two-day rest period may increase tolerability and effectiveness in continued edema control. Intravenous administration should be reserved for patients unable to take oral medications.</p></list-item><list-item><p>Bumetanide solution is not Y-site compatible with midazolam and is admixed incompatible with dobutamine and milrinone.</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hypercalcemia (off-label):
<list list-type="bullet"><list-item><p>1 to 4 mg IV every 1 to 4 hours; administer with saline to maintain the patient's urine output at 200 to 250 mL/hour.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hypertension (off-label):
<list list-type="bullet"><list-item><p>0.5 to 2.0 mg daily by mouth divided into one or two doses.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Renal dosing: in patients with anuria, bumetanide is contraindicated. In patients with hepatic failure,&#x000a0;dosing should&#x000a0;remain at a minimum level and, if&#x000a0;necessary,&#x000a0;should be increased&#x000a0;very&#x000a0;carefully.<xref ref-type="bibr" rid="article-32870.r1">[1]</xref><xref ref-type="bibr" rid="article-32870.r6">[6]</xref></p>
        <p>Data is lacking for the use of bumetanide in pregnancy and breastfeeding. No teratogenicity is expected based on data from other loop diuretics, although there is a potential risk for decreased placental perfusion based on the drug's mechanism of action. Clinicians should consider alternative therapy in patients breastfeeding high-risk infants.</p>
      </sec>
      <sec id="article-32870.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse events associated with bumetanide include hyperuricemia (characteristic of all loop diuretics), hypochloremia, hypokalemia, azotemia, and hyponatremia. Other less common adverse effects include hyperglycemia&#x000a0;and increased serum creatinine. muscle weakness, and hearing impairment.<xref ref-type="bibr" rid="article-32870.r8">[8]</xref><xref ref-type="bibr" rid="article-32870.r9">[9]</xref></p>
        <p>Rare but significant or potentially life-threatening adverse reactions include hypotension (including orthostatic hypotension), encephalopathy (in instances of pre-existing hepatic disease), and renal failure.<xref ref-type="bibr" rid="article-32870.r10">[10]</xref></p>
        <p>All loop diuretics exhibit potent diuresis capabilities, and excessive amounts can lead to significant diuresis with fluid and electrolyte loss; close medical supervision is necessary when administering these agents.</p>
      </sec>
      <sec id="article-32870.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Bumetanide&#x000a0;is contraindicated&#x000a0;in patients with hypersensitivity to the drug or components of the formulation. It&#x000a0;is also contraindicated&#x000a0;in patients with hypersensitivity to loop diuretics, hepatic disease, hepatic encephalopathy, severe electrolyte depletion, and anuria. Bumetanide&#x000a0;is in the FDA pregnancy risk category C classification. The safety and efficacy of bumetanide use have not been established in neonates, infants, children, and adolescents under the age of 18 years.<xref ref-type="bibr" rid="article-32870.r11">[11]</xref></p>
        <p>Complete medication reconciliation should be performed on all patients when adding any drug therapy, and bumetanide is no exception. Loop diuretics might enhance the hypotensive effect (specifically postural hypotension) and increase the nephrotoxicity of ACE inhibitors.<xref ref-type="bibr" rid="article-32870.r12">[12]</xref>&#x000a0;Other significant interactions also exist; the pharmacist should check for potential interactions and report any concerns to the prescriber so alternative therapy can be undertaken if necessary.</p>
      </sec>
      <sec id="article-32870.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Blood pressure, uric acid, jugular venous pressure, blood glucose, electrolytes, blood urea nitrogen/serum creatinine, and urine output must be monitored in patients taking bumetanide.&#x000a0;Bumetanide&#x000a0;is a potent diuretic; it can&#x000a0;precipitate electrolyte and acid-base imbalances such as&#x000a0;hypokalemia, hypocalcemia, hypochloremia, hyponatremia, hypomagnesemia, and metabolic alkalosis. It is essential to monitor urine output and serum electrolyte levels frequently. Dosage adjustments may be necessary, especially in patients treated for prolonged periods or with high doses; it is crucial that patients are monitored for hypokalemia, hypomagnesemia, and volume depletion resulting from excessive diuresis. Caution is also necessary for geriatric&#x000a0;patients who have&#x000a0;greater sensitivity to the hypotensive and diuretic effects of bumetanide.<xref ref-type="bibr" rid="article-32870.r13">[13]</xref></p>
        <p>The development of oliguria during therapy for patients with progressive renal disease is a sign to discontinue treatment with bumetanide. Blood and/or urine glucose levels should&#x000a0;be monitored&#x000a0;closely in diabetes mellitus&#x000a0;patients taking bumetanide because loop diuretics can impair glucose tolerance, leading to hyperglycemia. Signs and symptoms of hearing&#x000a0;impairment and tinnitus require attention from the clinician, as bumetanide may cause ototoxicity, with the dose adjusted accordingly. The cardiac function also requires monitoring as it may worsen heart failure and ventricular arrhythmias in patients with preexisting conditions.<xref ref-type="bibr" rid="article-32870.r14">[14]</xref></p>
      </sec>
      <sec id="article-32870.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Extensive or too frequent&#x000a0;dosage&#x000a0;can lead to acute volume and electrolyte depletion, low circulatory volume with a possibility of vascular thrombosis, and embolism. Symptoms such as weakness, mental confusion, anorexia, lethargy, vomiting, and cramps may occur&#x000a0;because&#x000a0;of electrolyte depletion. Treatment is with the adequate replacement of fluids and electrolytes, such as adding potassium supplements or potassium-sparing diuretics in case of potassium depletion. Asymptomatic&#x000a0;hyperuricemia&#x000a0;and slight reversible elevations of BUN and creatinine may also occur, particularly associated with dehydration or patients with&#x000a0;renal&#x000a0;insufficiency.&#x000a0;Bumetanide has shown&#x000a0;an increase&#x000a0;in urinary calcium with resultant hypocalcemia.&#x000a0;Similarly, hypomagnesemia should&#x000a0;be measured&#x000a0;periodically.<xref ref-type="bibr" rid="article-32870.r15">[15]</xref></p>
      </sec>
      <sec id="article-32870.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing&#x000a0;bumetanide therapy&#x000a0;requires an interprofessional team of healthcare professionals, including clinicians (MDs, DOs, NPs, PAs) in multiple specialties, nurses, and pharmacists. Ensuring the proper management of patients using bumetanide may require consideration of some of the following by health professionals:</p>
        <list list-type="bullet">
          <list-item>
            <p>There may be a need to involve specialty consultation depending on the reason for&#x000a0;diuretic therapy&#x000a0;and the patient's associated comorbidities.</p>
          </list-item>
          <list-item>
            <p>Ordering/prescribing clinicians should order serum electrolyte levels periodically and check for any fluid or electrolyte imbalance.</p>
          </list-item>
          <list-item>
            <p>Monitor the patient for signs of dehydration frequently, such as low urine output,&#x000a0;etc. Taking prompt action can be beneficial and&#x000a0;even lifesaving. It is&#x000a0;critical to follow up on serum electrolyte levels. Proper dose adjustments can be crucial in improving the various conditions discussed above in the indications section.</p>
          </list-item>
          <list-item>
            <p>Hypokalemia&#x000a0;must be ruled out,&#x000a0;as it can be an alarming sign of impending cardiac arrhythmia, especially for those patients with a history of ventricular arrhythmia.</p>
          </list-item>
          <list-item>
            <p>Discuss and consult with a toxicologist and nephrologist if an overdose is suspected.</p>
          </list-item>
          <list-item>
            <p>Provide reassurance for asymptomatic hyperuricemia and azotemia in patients with signs of dehydration, as they are likely to resolve after fluid replacement.&#x000a0;</p>
          </list-item>
        </list>
        <p>Utilizing an interprofessional approach with each discipline sharing patient information and their particular clinical expertise will provide the best patient outcomes while minimizing adverse events. [Level 5]</p>
      </sec>
      <sec id="article-32870.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32870&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32870">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/32870/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=32870">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-32870.s11">
        <title>References</title>
        <ref id="article-32870.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flamenbaum</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new "loop" diuretic.</article-title>
            <source>Pharmacotherapy</source>
            <year>1982</year>
            <season>Jul-Aug</season>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>213</fpage>
            <page-range>213-22</page-range>
            <pub-id pub-id-type="pmid">6763204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacifici</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.</article-title>
            <source>Paediatr Drugs</source>
            <year>2012</year>
            <month>Aug</month>
            <day>01</day>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>233</fpage>
            <page-range>233-46</page-range>
            <pub-id pub-id-type="pmid">22702741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Andel</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sprengers</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Oranje</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scheepers</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Bruining</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.</article-title>
            <source>Mol Autism</source>
            <year>2020</year>
            <month>May</month>
            <day>07</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">32381101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kokko</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Site and mechanism of action of diuretics.</article-title>
            <source>Am J Med</source>
            <year>1984</year>
            <month>Nov</month>
            <day>05</day>
            <volume>77</volume>
            <issue>5A</issue>
            <fpage>11</fpage>
            <page-range>11-7</page-range>
            <pub-id pub-id-type="pmid">6496555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayakumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puschett</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Study of the sites and mechanisms of action of bumetanide in man.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1977</year>
            <month>Apr</month>
            <volume>201</volume>
            <issue>1</issue>
            <fpage>251</fpage>
            <page-range>251-8</page-range>
            <pub-id pub-id-type="pmid">850144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pentik&#x000e4;inen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Penttil&#x000e4;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gothoni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Fate of [14C]-bumetanide in man.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1977</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-44</page-range>
            <pub-id pub-id-type="pmid">843423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000fc;low</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ladefoged</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>[Loop diuretics. Rational pharmacotherapy].</article-title>
            <source>Ugeskr Laeger</source>
            <year>1993</year>
            <month>Nov</month>
            <day>01</day>
            <volume>155</volume>
            <issue>44</issue>
            <fpage>3563</fpage>
            <page-range>3563-6</page-range>
            <pub-id pub-id-type="pmid">8236578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Homeida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bogie</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1978</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-33</page-range>
            <pub-id pub-id-type="pmid">678389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Diuretics: mechanism of action and clinical application.</article-title>
            <source>Drugs</source>
            <year>1975</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-226</page-range>
            <pub-id pub-id-type="pmid">1092541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>426</fpage>
            <page-range>426-64</page-range>
            <pub-id pub-id-type="pmid">6391889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sung</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lovinger</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Delpire</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Abnormal GABAA receptor-mediated currents in dorsal root ganglion neurons isolated from Na-K-2Cl cotransporter null mice.</article-title>
            <source>J Neurosci</source>
            <year>2000</year>
            <month>Oct</month>
            <day>15</day>
            <volume>20</volume>
            <issue>20</issue>
            <fpage>7531</fpage>
            <page-range>7531-8</page-range>
            <pub-id pub-id-type="pmid">11027211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <article-title>Comparison chart: Some drugs for HFrEF.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2021</year>
            <month>Jun</month>
            <day>14</day>
            <volume>63</volume>
            <issue>1626</issue>
            <fpage>e1</fpage>
            <page-range>e1-e14</page-range>
            <pub-id pub-id-type="pmid">34181629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Claggett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kachadourian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lefkowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>337</fpage>
            <page-range>337-341</page-range>
            <pub-id pub-id-type="pmid">30741494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allegaert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lahav</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van den Anker</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Erratum to: A Mechanism to Explain Ototoxicity in Neonates Exposed to Bumetanide: Lessons to Help Improve Future Product Development in Neonates.</article-title>
            <source>Paediatr Drugs</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>475</fpage>
            <pub-id pub-id-type="pmid">27665286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32870.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hung</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Bumetanide attenuates acute lung injury by suppressing macrophage activation.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>156</volume>
            <fpage>60</fpage>
            <page-range>60-67</page-range>
            <pub-id pub-id-type="pmid">30102895</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
